



AinShams Universty

Faculty of Science

Chemistry Department

# **Clinical Utility of Serum Glycodelin as a Novel Marker for Ovarian Cancer**

Thesis Submitted by

**Mohamed Samir Abd-Allah Mahmoud Hegab**

(M.Sc. in Chemistry 2009)

**In the Fulfillment of the requirements for a (Ph. D)  
degree in Analytical Chemistry**

**Supervised by**

***Prof. Dr. Ibrahim H. A. Badr***

Professor of Analytical Chemistry

Faculty of Science, Ain Shams University

***Prof. Dr. Helmy Matawe El Sayed***

Professor of Gynecology and Obstetrics

Faculty of Medicine, Ain Shams University

**Dr. Hala Abdel Al Ahmed**

Lecturer of Clinical and Chemical Pathology

Faculty of Medicine, Ain Shams University

Ain Shams University

Faculty of Science

Chemistry Department

2013

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا  
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة آية (32)



First of all, all gratitude is due to **Allah** for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

I would like to express my deep gratitude to **Prof. Dr. Ibrahim Hosiny Ali Badr**. Professor of Analytical Chemistry, Faculty of Science, Ain Shams University. I am greatly indebted to him for suggesting and planning the subject, supervising the whole work, reading and criticizing the manuscript. I will never forget his unlimited help, continuous support, kind encouragement, constructive criticism and wise guidance. To his words of praise are not sufficient and I am really greatly indebted to him.

Also I am greatly indebted to **Prof Dr. Helmy Matawe El Sayed** Professor of Gynecology and Obstetrics, Faculty of Medicine, Ain Shams University, for his helpful guidance, valuable advice, meticulous care, great effort and generous help in this work.

I wish also to express my utmost thanks to **Dr. Hala Abdel Al Ahmed**, lecture of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her generous help and support throughout every step in this work.

Finally, I would like to express sincerely my gratitude to **my mother, my father, my wife and my son** for their immense help, tolerance and support and to them I dedicate this work.

**Mohamed hegab**



AinShams Universty  
Faculty of Science  
Chemistry Department

# **Clinical Utility of Serum Glycodelin as a Novel Marker for Ovarian Cancer**

**Thesis Submitted by**

**Mohamed Samir Abd-Allah Mahmoud Hegab**

(M.Sc. in Chemistry 2009)

Benha University

**In the Fulfillment of the requirements for a (Ph. D)**

**degree in Analytical Chemistry**

Ain Shams University

Faculty of Science

Chemistry Department

2013

## *List of Contents*

| <i>Title</i>                                 | <i>Page</i> |
|--|-------------|
| INTRODUCTION .....                           | 1           |
| SUBJECTS AND METHODS .....                   | 63          |
| RESULTS .....                                | 79          |
| DISCUSSION .....                             | 94          |
| Summary .....                                | 100         |
| References .....                             | 105         |
| الملخص العربى .....                          | 1           |
| الطالب / محمد سمير عبد الله محمود حجاب ..... | 1           |
| <b>Arabic summary</b>                        |             |

## *List of Tables*

| <i>Table No</i> | <i>Title</i>  | <i>Page</i> |
|-----------------|---|-------------|
| Table (1):      | WHO Histological Classification of Ovarian Tumors .....   | 15          |
| Table (2):      | Pathological Classification of Ovarian Tumors .....   | 17          |
| Table (3):      | T N M Classification of Ovarian Tumors .....  | 18          |
| Table (4):      | Staging of Ovarian Cancer .....   | 19          |
| Table (5):      | Grading of Ovarian Cancer .....   | 20          |
| Table (6):      | Descriptive statistics of the demographic data and the studied parameters in the different studied groups.....                    | 82          |
| Table (7):      | Statistical comparison between different groups regarding the studied parameters using Wilcoxon's Rank Sum Test . .....           | 83          |
| Table (8):      | Descriptive and comparative statistics between different subgroups of ovarian cancer patients using Wilcoxon's Rank sum Test..... | 84          |
| Table (9):      | Correlation analysis between glyodelin and different studied parameters using Sperman's rank correlation test. ....               | 85          |
| Table (10):     | Diagnostic performance of serum Glycodelin in discrimination between different studied groups. ....                               | 86          |

## *List of Figures*

| <i>Figure No.</i>   | <i>Title</i>   | <i>Page</i> |
|---------------------|--|-------------|
| <b>Figure (1):</b>  | Radioimmunoassay method of glycodelin. ....  | 57          |
| <b>Figure (2):</b>  | ELISA method of glycodelin. ....   | 59          |
| <b>Figure (3):</b>  | In Situ Hybridization method of glycodelin. ....   | 62          |
| <b>Figure (4):</b>  | Diagram showing the principle of CA-125 assay by ECLIA. ....   | 69          |
| <b>Figure (5):</b>  | Comparison between all studied groups as regards CA125 and Glycodelin. ....                                      | 87          |
| <b>Figure (6):</b>  | Comparison between grades as regards CA-125 and Glycodelin. ....   | 88          |
| <b>Figure (7):</b>  | Linear regression analysis showing Correlation between CA125 and Glycdelin among malignant group. ....           | 89          |
| <b>Figure (8):</b>  | Linear regression analysis showing Correlation between CA125 and Glycdelin among benign group. ....              | 90          |
| <b>Figure (9):</b>  | ROC curve analysis showing the diagnostic performance of GD for discriminating benign from control. ..           | 91          |
| <b>Figure (10):</b> | ROC curve analysis showing the diagnostic performance of GD for discriminating malignant from those benign. .... | 92          |
| <b>Figure (11):</b> | ROC curve analysis showing the diagnostic performance of GD for discriminating grade 3+4 from those 1+2. ....    | 93          |

## *List of Abbreviations*

|               |                                     |
|---------------|-------------------------------------|
| $\alpha$      | Alph                                |
| $\beta$       | Beta                                |
| <b>AFP</b>    | Alpha fetoprotein                   |
| <b>AJCC</b>   | American Joint Committee on Cancer  |
| <b>AML</b>    | Acute myeloid leukemia              |
| <b>AUC</b>    | Area under curve                    |
| <b>AUP</b>    | $\alpha$ -uterine protein           |
| <b>BRCA</b>   | Breast cancer susceptibility gene 1 |
| <b>BRCA</b>   | Breast cancer susceptibility gene 2 |
| <b>brp-39</b> | Breast regressing protein 39        |
| <b>bp</b>     | (base-pair)                         |
| <b>bpy</b>    | 2,2-bipy                            |
| <b>CA-125</b> | Cancer antigen 125                  |
| <b>CA15-3</b> | Carbohydrate antigen15-3            |
| <b>CA19-9</b> | Carbohydrate antigen19-9            |
| <b>CASA</b>   | Cancer associated serum antigen     |
| <b>CAG-2</b>  | chorionic $\alpha$ 2-microglobulin  |
| <b>CBC</b>    | Complete blood picture              |
| <b>CD</b>     | Cluster differentiation             |



|               |   |
|---------------|---|
| <b>cDNA</b>   | Complementary deoxyribonucleic acid                   |
| <b>CEA</b>    | Carcinomabryonic antigen                              |
| <b>CT</b>     | Computed Tomography                                   |
| <b>CAG</b>    | chorionic $\alpha$ 2-globulin                         |
| <b>DNA</b>    | Deoxyribonucleic acid                                 |
| <b>ECLIA</b>  | Electrochemiluminescence immunoassay                  |
| <b>EDTA</b>   | Ethylene Diamine Tetra actetic Acid                   |
| <b>ELISA</b>  | Enzyme linked immunsorbant assay                      |
| <b>ER</b>     | Estrogen receptor                                     |
| <b>EGFR</b>   | epidermal growth factor receptor                      |
| <b>ErbB-1</b> | epidermal growth factor receptor B-1                  |
| <b>FIGO</b>   | International Federation of Gynecology and Obstetrics |
| <b>FISH</b>   | Flourescent In Situ Hybridization                     |
| <b>GdA</b>    | glycodelin-A  |
| <b>GdC</b>    | glycodelin-C  |
| <b>GdF</b>    | glycodelin-F  |

|              |   |
|--------------|---|
| <b>GdS</b>   | glycodelin-S                                |
| <b>HC</b>    | Human Cartilage glycol-protein-39           |
| <b>gp39</b>  |   |
| <b>HCG</b>   | Human chorionic gonadotropin                |
| <b>HER2</b>  | Human epidermal growth factor<br>receptor 2 |
| <b>HIV</b>   | Human Immunodeficiency Virus                |
| <b>hk</b>    | Human kallikrein                            |
| <b>IAP</b>   | Immunosuppressive acid protein              |
| <b>IL</b>    | interleukin                                 |
| <b>IR</b>    | Interquartile range                         |
| <b>IVF</b>   | In Vitro Fertilization                      |
| <b>kDa</b>   | Kilo Daltons                                |
| <b>LDH</b>   | Lactate dehydrogenase                       |
| <b>LGLs</b>  | large granular lymphocytes                  |
| <b>LPA</b>   | Lysophosphatidic acid                       |
| <b>mAb</b>   | monoclonal antibodies                       |
| <b>MCF-7</b> | Macrophage colony factor                    |
| <b>MCS-F</b> | Macrophage colony stimulating<br>factor     |
| <b>MRI</b>   | Magnetic Resonance Imaging                  |

|                                 |  |
|---------------------------------|--|
| <b>MLH</b>                      | Mutl-homolog gene                                      |
| <b>MSH</b>                      | Melanocyte- Stimulating hormone                        |
| <b>MMAC</b>                     | Multiply accumulates gene                              |
| <b>mRNA</b>                     | Messenger ribonucleic acid                             |
| <b>n</b>                        | Number   |
| <b>NAD</b>                      | $\beta$ -nicotinamide adenine dinucleotide             |
| <b>NADH</b>                     | Reduced $\beta$ - nicotinamide adenine<br>dinucleotide |
| <b>NK</b>                       | natural killer   |
| <b>PAEP</b>                     | progesterone-associated endometrial<br>protein         |
| <b>PC</b>                       | Prostate carcinoma                                     |
| <b>P53</b>                      | tumor suppressor gene                                  |
| <b>PCOS</b>                     | Polycystic ovarian syndrome                            |
| <b><math>\alpha</math>2-PEG</b> | pregnancy-associated $\alpha$ 2-<br>microglobulin      |
| <b>PCR</b>                      | Polymerase chain reaction                              |
| <b>PEP</b>                      | progesterone-associated endometrial<br>protein         |
| <b>PET</b>                      | Positron emission tomography                           |
| <b>PMS</b>                      | Premenstrual Dysphoric Disorder                        |

|                      |  |
|----------------------|--|
| <b>PP14</b>          | placental protein 14                                 |
| <b>PR</b>            | Progesterone receptor                                |
| <b>PTEN</b>          | Phosphatase and Tenis Homolog<br>gene                |
| <b>RIA</b>           | Radioimmunoassay                                     |
| <b>RNA</b>           | Ribonucleic acid                                     |
| <b>r<sub>s</sub></b> | Spearman's Rank correlation<br>coefficient           |
| <b>RTK</b>           | Receptor tyrosine kinase                             |
| <b>RT-PCR</b>        | Reverse transcriptase polymerase<br>chain reaction   |
| <b>ROC</b>           | Receiver operating characteristic                    |
| <b>RU</b>            | : ruthenium  |
| <b>SD</b>            | Standard deviation                                   |
| <b>SSO,S</b>         | Sequence -specific oligonucleotides                  |
| <b>TAG</b>           | Tumor associated glycoprotein                        |
| <b>TATI</b>          | Tumor- associated trypsin inhibitor                  |
| <b>TEP</b>           | Total Extraperitoneal Inguinal hernia<br>repair gene |
| <b>T.N.M</b>         | Tumor Size, Node Involvement,<br>Metastasis Status   |
| <b>TPA</b>           | tripropylamine                                       |
| <b>U/S</b>           | Ultrasound   |
| <b>WHO</b>           | World Healthy Organization                           |



## **Referees Decision**

**Title: "Clinical Utility of Serum Glycodelin as a Novel Marker for  
Ovarian Cancer"**

**Presented by: Mohamed Samir Abd Allah Mahmoud Hegab**

### **Referees**

|   | Name  | Position  | Signature |
|---|---|---|-----------|
| 1 | <b>Prof. Dr./ Raga El<br/>Sheikh Sheb</b>           | <b>Professor of Analytical<br/>chemistry, Faculty of Science,<br/>Zagazig University Professor of</b>                 |           |
| 2 | <b>Prof. Dr. / Ibrahim<br/>Hosiny Ali Badr</b>      | <b>Professor of Analytical chemistry,<br/>Faculty of Science, Ain shams<br/>University</b>                            |           |
| 3 | <b>Ass.Prof. Dr./<br/>Nermine Helmy<br/>Mahmoud</b> | <b>Assistant Professor of Clinical<br/>and Chemical Pathology,<br/>Faculty of Medicine, Ain Shams<br/>University.</b> |           |

**Date of Discussion:**

**Degree of Discussion:**

**Head of Chemistry Department**

**Prof. Dr. Maged Shafik Auntonious Nakhla**

# INTRODUCTION

Ovarian cancer is considered the most challenging gynecological malignancy as it represents the fifth most frequent female cancer type and the fourth most frequent cause of death from cancer (*Hogdall et al., 2003*). Approximately 70% of ovarian cancer is diagnosed in an advanced stage and only 35% of patients survive for 5 years, with mortality rate largely unchanged for many years (*Crijns et al., 2009*).

CA- 125 was the first tumor marker available for detection of ovarian cancer but the major problem is its poor sensitivity and specificity as it is elevated in only 40% - 50% of patients with stage I and II ovarian cancer and can be detected also in benign conditions as pregnancy, endometriosis, ovarian cyst and liver cirrhosis (*Dupont et al., 2004*).

Glycodelin is the major lipocalin protein of the reproductive axis. Glycodelin has many immunosuppressive, contraceptive and morphogenic properties (*Alok and Karande, 2009*). Glycodelin has by many names in the literature including placental protein 14 (PP14), chorionic  $\alpha 2$ -microglobulin (CAG-2), progesterone-associated endometrial protein (PEP), and pregnancy-associated  $\alpha 2$ -microglobulin ( $\alpha 2$ -PEG) (*Yeung et al., 2009*). Glycodelin had been originally purified from human term placenta and its adjacent membranes, and it was thought to be pregnancy specific. Because it was evident, that human endometrium was its major source, the name progesterone-

associated endometrial protein was suggested (*Alok and Karande, 2009*). However, Glycodelin is not exclusive to the endometrium as it was detected in the normal human ovary and was localized to areas of stromal cell condensation in ovarian cortex, theca interna and the granulosa in the follicular phase, and to the theca interna of the corpus luteum and luteinized granulosa cells, corpus albicans and the Leydig cells of the ovarian hilus in the luteal phase (*Bersinger et al., 2009*).